Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Coloplast on the acquisition of Atos Medical
Mandate

Vinge advises Coloplast on the acquisition of Atos Medical

November 11, 2021 Employment and Benefits Real Estate and Construction Banking and Finance Corporate Crime & Compliance IT, Telecommunications and Outsourcing Intellectual Property M&A

Vinge advises Danish healthcare company Coloplast on its acquisition of Atos Medical, the global market leader in laryngectomy for EUR 2.155 billion (around DKK 16 billion) from PAI Partners, a global private equity firm headquartered in Paris. Closing of the transaction is subject to customary regulatory approvals and anticipated to occur in Q2 2021/22.

Vinge’s team primarily consisted of Matthias Pannier, Ulrich Ziche, Vilhelm Rondahl, Clara Sohlberg and Julia Hagelberg (M&A), Klara Secher and Axel Lennartsson (IP), Lisa Hörnqvist and Mario Saad (Agreements and IT), Karl-Hugo Engdahl and Karolina Fuhrman (GDPR), Tove Lövgren Frisk (Compliance), Jolinn Uhlin and Michaela Ådén (Banking & Financing), Elin Broman (Employment) and Lina Österberg and Ulf Pyk (Real Estate). Kromann Reumert acted as lead counsel for Coloplast.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026